Key result
Rapid up-titration of foundational medical therapy reduces 180-day death or HF readmission across risk strata.
Why the study?
Does early, comprehensive, high-intensity foundational medical therapy reduce morbidity and mortality across different baseline risk profiles in patients with heart failure with reduced ejection fraction (HFrEF)?
Does early, comprehensive, high-intensity foundational medical therapy reduce morbidity and mortality across different baseline risk profiles in patients with heart failure with reduced ejection fraction (HFrEF)?
Available evidence supports early initiation and structured optimization of foundational medical therapy in appropriately selected HFrEF patients across risk profiles, indicating that higher baseline risk alone does not justify therapeutic inertia.
Answers are grounded in this paper and cite their sources.
Supports early high-intensity FMT across HFrEF risk strata without inertia; leaves open optimal sequencing, dosing, and targets for prospective study.
Heart failure (HF) is a major global health challenge, characterized by high morbidity, mortality, frequent hospitalization, and substantial healthcare costs, despite recent therapeutic advances. In heart failure with reduced ejection fraction (HFrEF; LVEF < 50%), foundational medical therapy (FMT), as defined in the 2026 European Society of Cardiology (ESC) guidelines-comprising renin-angiotensin system inhibition or angiotensin receptor-neprilysin inhibitors, beta-blockers, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter-2 inhibitors-reduces morbidity and mortality, but its benefit depends on how completely, how quickly, and how intensively these therapies are implemented. This narrative review evaluates whether the benefit of early, comprehensive, high-intensity FMT in HFrEF differs according to specific baseline risk modifiers, drawing on the STRONG-HF trial and its secondary analyses, other randomized evidence, and real-world studies. In STRONG-HF, a high-intensity care strategy that combined rapid up-titration of renin-angiotensin system inhibitors, beta-blockers, and mineralocorticoid receptor antagonists with close post-discharge follow-up reduced the composite of all-cause death or HF readmission at 180 days, driven mainly by fewer HF readmissions; all-cause mortality alone was not significantly reduced, and sodium-glucose cotransporter-2 inhibitors were not part of the protocolized strategy. Secondary analyses found no significant heterogeneity of this effect across MAGGIC risk tertiles or systolic blood pressure strata, whereas associations between higher attained doses and better outcomes were observational. Meta-analyses of randomized trials additionally support early initiation of mineralocorticoid receptor antagonists and sodium-glucose cotransporter-2 inhibitors after decompensation. Prognostic scores, physiological parameters, and treatment-exposure measures are treated as distinct constructs rather than as an interchangeable single risk category. The review also addresses tools for risk prognostication, the boundary between FMT optimization and evaluation for mechanical circulatory support in advanced HF, and the real-world barriers to implementation, including patient comorbidity, therapeutic inertia, health-system constraints, and cost. Available evidence supports early initiation and structured optimization of FMT in appropriately selected HFrEF patients, with no convincing evidence that higher baseline risk alone justifies therapeutic inertia; however, the independent contributions of treatment completeness, dose intensity, and monitoring intensity, the optimal sequencing, and individualized dose targets remain uncertain, particularly in very high-risk and underrepresented populations, and warrant further prospective study.
No takes yet. Share an insight, caveat, or question.
Laxmi et al. (2026) conducted a review in Heart failure with reduced ejection fraction (HFrEF; LVEF < 50%). Early, comprehensive, high-intensity foundational medical therapy (renin-angiotensin system inhibitors or ARNI, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors) was evaluated on Composite of all-cause death or heart failure readmission at 180 days (in STRONG-HF). High-intensity foundational medical therapy with rapid up-titration reduced 180-day all-cause death or HF readmission in STRONG-HF without heterogeneity across MAGGIC risk or SBP strata.
Synapse has enriched 10 related papers. Consider them for comparative context: